ASX:CYP

Cynata Therapeutics Competitors

Add

Compare

Today's Range N/A

50-Day Range

A$0.68

MA: A$0.68▼

A$0.68

52-Week Range N/A

Volume159,853 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Cynata Therapeutics (ASX:CYP) Vs. CHV, DDXS, PREV, TNGN, COM, and MYM

Should you be buying CYP stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Cynata Therapeutics, including (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), and 17031 (MYM).

Cynata Therapeutics vs. (CHV) Stock

(CHV) (CNSX:CHV) and Cynata Therapeutics (ASX:CYP) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Profitability

This table compares (CHV) and Cynata Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(CHV)	N/A	N/A	N/A
Cynata Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for (CHV) and Cynata Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(CHV)	0	0	0	0	N/A
Cynata Therapeutics	0	0	0	0	N/A

Valuation & Earnings

This table compares (CHV) and Cynata Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(CHV)	N/A	N/A	N/A	N/A	N/A
Cynata Therapeutics	$7.01 million	0.00	$-5,014,694.72	A($0.04)	N/A

(CHV) has higher earnings, but lower revenue than Cynata Therapeutics.

Summary

Cynata Therapeutics beats (CHV) on 1 of the 1 factors compared between the two stocks.

Cynata Therapeutics vs. (DDXS) Stock

(DDXS) (OTCMKTS:DDXS) and Cynata Therapeutics (ASX:CYP) are both health technology companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Profitability

This table compares (DDXS) and Cynata Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(DDXS)	N/A	N/A	N/A
Cynata Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for (DDXS) and Cynata Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(DDXS)	0	0	0	0	N/A
Cynata Therapeutics	0	0	0	0	N/A

Valuation & Earnings

This table compares (DDXS) and Cynata Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(DDXS)	N/A	N/A	N/A	N/A	N/A
Cynata Therapeutics	$7.01 million	0.00	$-5,014,694.72	A($0.04)	N/A

(DDXS) has higher earnings, but lower revenue than Cynata Therapeutics.

Summary

Cynata Therapeutics beats (DDXS) on 1 of the 1 factors compared between the two stocks.

Cynata Therapeutics vs. (PREV) Stock

(PREV) (CNSX:PREV) and Cynata Therapeutics (ASX:CYP) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Valuation & Earnings

This table compares (PREV) and Cynata Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(PREV)	N/A	N/A	N/A	N/A	N/A
Cynata Therapeutics	$7.01 million	0.00	$-5,014,694.72	A($0.04)	N/A

(PREV) has higher earnings, but lower revenue than Cynata Therapeutics.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for (PREV) and Cynata Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(PREV)	0	0	0	0	N/A
Cynata Therapeutics	0	0	0	0	N/A

Profitability

This table compares (PREV) and Cynata Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(PREV)	N/A	N/A	N/A
Cynata Therapeutics	N/A	N/A	N/A

Summary

Cynata Therapeutics beats (PREV) on 1 of the 1 factors compared between the two stocks.

Cynata Therapeutics vs. (TNGN) Stock

Cynata Therapeutics (ASX:CYP) and (TNGN) (OTCMKTS:TNGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Earnings and Valuation

This table compares Cynata Therapeutics and (TNGN)'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cynata Therapeutics	$7.01 million	0.00	$-5,014,694.72	A($0.04)	N/A
(TNGN)	N/A	N/A	N/A	N/A	N/A

(TNGN) has lower revenue, but higher earnings than Cynata Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations for Cynata Therapeutics and (TNGN), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cynata Therapeutics	0	0	0	0	N/A
(TNGN)	0	0	0	0	N/A

Profitability

This table compares Cynata Therapeutics and (TNGN)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cynata Therapeutics	N/A	N/A	N/A
(TNGN)	N/A	N/A	N/A

Summary

Cynata Therapeutics beats (TNGN) on 1 of the 1 factors compared between the two stocks.

Cynata Therapeutics vs. 138267 (COM.TO) Stock

Cynata Therapeutics (ASX:CYP) and 138267 (COM.TO) (TSE:COM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Earnings and Valuation

This table compares Cynata Therapeutics and 138267 (COM.TO)'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cynata Therapeutics	$7.01 million	0.00	C$-5,014,694.72	A($0.04)	N/A
138267 (COM.TO)	N/A	N/A	N/A	N/A	N/A

138267 (COM.TO) has lower revenue, but higher earnings than Cynata Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations for Cynata Therapeutics and 138267 (COM.TO), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cynata Therapeutics	0	0	0	0	N/A
138267 (COM.TO)	0	0	0	0	N/A

Profitability

This table compares Cynata Therapeutics and 138267 (COM.TO)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cynata Therapeutics	N/A	N/A	N/A
138267 (COM.TO)	N/A	N/A	N/A

Summary

Cynata Therapeutics beats 138267 (COM.TO) on 1 of the 1 factors compared between the two stocks.

Cynata Therapeutics vs. 17031 Stock

Cynata Therapeutics (ASX:CYP) and 17031 (CNSX:MYM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Earnings and Valuation

This table compares Cynata Therapeutics and 17031's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cynata Therapeutics	$7.01 million	0.00	C$-5,014,694.72	A($0.04)	N/A
17031	N/A	N/A	N/A	N/A	N/A

17031 has lower revenue, but higher earnings than Cynata Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations for Cynata Therapeutics and 17031, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cynata Therapeutics	0	0	0	0	N/A
17031	0	0	0	0	N/A

Profitability

This table compares Cynata Therapeutics and 17031's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cynata Therapeutics	N/A	N/A	N/A
17031	N/A	N/A	N/A

Summary

Cynata Therapeutics beats 17031 on 1 of the 1 factors compared between the two stocks.